A Study of GH21 Combined With Previous Target Therapy or Immunotherapy in Patients With Advanced Solid Tumors

NCT06322095 ↗

Phase 2 Unknown 72 enrolled Suzhou Genhouse Bio Co., Ltd.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is aim to evaluate the preliminary efficacy of GH21 combined with previous target therapy or immunotherapy in patients with advanced solid tumors.

Timeline

Start: 2024-03-22
Primary completion: 2025-09-30
Completion: 2025-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GH21	Unknown	6 mg	Oral
Subject	GH21	Unknown	15 mg	Oral

Indications

No indication recorded.